Molecular imaging of ovarian cancer: Sharma and colleagues survey recent advances and emerging innovations in MR, PET, SPECT, ultrasound, and optical imaging of ovarian cancer.
Page 827
Brachytherapy with 177Lu-AuNPs: Ehlerding and Cai offer perspective on brachytherapy in locally advanced breast cancer and preview a related article in this issue of JNM on intratumorally injected gold nanoparticles labeled with radiotherapeutic 177Lu.
Page 834
131I and cataracts: Lin and colleagues evaluate associations between 131I therapy and cataract surgery over a 10-year period after thyroid cancer treatment.
Page 836
PET textural features in NSCLC: Ohri and colleagues use cooperative trial data to determine whether heterogeneity metrics from 18F-FDG PET textural features can provide prognostic information in patients treated with chemoradiation for locally advanced non–small cell lung cancer.
Page 842
Background-adapted response assessment: Burger and colleagues investigate correlations between background-subtracted lesion activity/background-subtracted volume on 18F-FDG PET and histopathologic response after chemotherapy in non–small cell lung carcinoma.
Page 849
PET/CT lung cancer therapy response: Sheikhbahaei and colleagues assess the value of an 18F-FDG PET/CT–based 5-point Hopkins interpretation system in predicting therapy response and survival in lung cancer.
Page 855
Kinetic analysis of 11C-erlotinib: Yaqub and colleagues identify an optimal pharmacokinetic model for quantification of 11C-erlotinib uptake in patients with non–small cell lung cancer and evaluate simplified methods for routine analysis.
Page 861
68Ga-labeled ABY-025 dosimetry: Sandström and colleagues measure biodistribution and estimate radiation dosimetry for this radiolabeled Affibody molecule in 2 different peptide mass doses using dynamic and serial whole-body PET/CT in patients with metastatic breast cancer.
Page 867
Assessing 68Ga-DOTATATE: Deppen and colleagues report on a systematic review and analysis of the safety and efficacy of 68Ga-DOTATATE PET/CT compared with octreotide and conventional imaging to determine whether available evidence supports FDA approval.
Page 872
PET/CT in endometrial cancer: Bollineni and colleagues analyze the reported diagnostic performance of 18F-FDG PET/CT for preoperative assessment of lymph node metastases in endometrial cancer and in recurrence after primary surgical treatment.
Page 879
Na18F PET/CT in advanced prostate cancer: Apolo and colleagues detail the results of a pilot study on Na18F PET/CT detection and monitoring of bone metastases in advanced prostate cancer and identify correlations with clinical outcomes and survival.
Page 886
SPECT quantification and dose reduction: Palyo and colleagues demonstrate the dose reduction capabilities of a hybrid cadmium-zinc-telluride SPECT/64-slice CT system and determine the maximum reduction possible without compromising image quality or myocardial perfusion quantification precision.
Page 893
Interpreting florbetaben PET: Seibyl and colleagues test the robustness of visual assessment in 18F-florbetaben scans, comparing efficacy readouts across different interpreters and training methods and against a histopathology standard in end-of-life patients with and without dementia.
Page 900
18F-FDG and 11C-acetate PET/CT dosimetry: Liu and colleagues characterize the radiation dosimetry of this combined whole-body dual-tracer PET/CT protocol used in staging patients with hepatocellular carcinoma.
Page 907
MR AC and amyloid PET: Su and colleagues investigate the impact of a standard MR attenuation correction technique on the clinical and research utility of a hybrid PET/MR scanner in assessment of amyloid status.
Page 913
Brain PET/MR AC: Koesters and colleagues describe a novel attenuation correction method that supplements standard Dixon-based tissue segmentation with a superimposed model-based bone compartment in simultaneous PET and MR brain imaging.
Page 918
Albumin microspheres in radioembolization: Grosser and colleagues explore the intrahepatic and intrapulmonary stability of 99mTc-macroaggregated serum albumin and 99mTc-human serum albumin for perfusion scintigraphy before hepatic radioembolization with 90Y-microspheres.
Page 925
Lymphoma response assessment criteria: Moghbel and colleagues provide an educational overview of existing response assessment criteria for lymphoma, highlighting their respective methodologies and reviewing evidence for validity.
Page 928
177Lu gold nanoseed brachytherapy: Yook and colleagues study intratumorally injected 177Lu-labeled gold nanoparticles modified to target epidermal growth factor receptors as a novel neoadjuvant brachytherapy approach in preclinical models of locally advanced breast cancer.
Page 936
Targeting CAIX-positive kidney cancer: Krall and colleagues investigate the biodistribution of a novel carbonic anhydrase ligand with high affinity for the tumor-associated isoform IX and assess evidence supporting further development of acetazolamide conjugates as drug carriers and radioimaging agents.
Page 943
Imaging MC-I activity in PD: Tsukada and colleagues describe the use of 18F-BCPP-EF PET to assess mitochondrial complex I activity and damage in the brains of nonhuman primate models of Parkinson disease.
Page 950
Neuroinflammation and amyloidosis in AD mice: Brendel and colleagues detail the results of a triple-tracer small-animal PET investigation to study microglial activation and glucose metabolism in association with amyloid plaque load in a transgenic Alzheimer disease mouse model.
Page 954
Hepatobiliary secretion kinetics: Sørensen and colleagues develop a method for 11C-CSar PET quantification of hepatobiliary uptake and secretion of conjugated bile acids in pigs.
Page 961
18F-labeled anti-HER2 Nanobody: Vaidyanathan and colleagues use 2 methods to evaluate the tumor-targeting potential of an anti–human growth factor receptor type 2 Nanobody for applications in immuno-PET assessment of HER2 status.
Page 967
89Zr-DS-8895a imaging of EphA2: Burvenich and colleagues report on preclinical SPECT/MR and PET/MR imaging of subtype A2 of the erythropoietin-producing hepatocellular tyrosine kinase, a cell surface receptor expressed in a range of epithelial cancers.
Page 974
ACKR3/CXCR7 tumor imaging: Behnam Azad and colleagues describe evaluation of a radiolabeled atypical chemokine receptor–targeted monoclonal antibody for noninvasive nuclear imaging of ACKR3 expression in human breast, lung, and esophageal squamous cell carcinoma xenografts.
Page 981
- © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Jump to section
Related Articles
Cited By...
- No citing articles found.